1280666-41-2

Upstream product

• 104-63-2 N-Benzylethanolamine 
• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 620604-44-6 methyl 7-nitrobenzofuran-4-carboxylate 
• 1030837-46-7 3-(benzyl(2-hydroxyethyl)amino)-2-chloro-propanenitrile 
• 110859-47-7 (4-benzylmorpholin-2-yl)methanamine 
• 1280665-55-5 methyl 7-amino-2,3-dihydro-1-benzofuran-4-carboxylate 
• 1280665-61-3 methyl 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxylate 
• 1280665-63-5 7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxylic acid 
• 214273-17-3 [(2R)-4-benzylmorpholin-2-yl]methanamine 
• 620604-43-5 methyl 2-hydroxy-7-nitro-2,3-dihydrobenzofuran-4-carboxylate 
• 326799-92-2 methyl 4-nitro-3-(prop-2-en-1-yloxy)benzoate 
• 713-52-0 methyl 3-hydroxy-4-nitrobenzoate 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 

Relevant academic research and scientific papers

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.